Active Ingredient History
Trimethoprim (TMP) is an antibiotic is used for the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. Trimethoprim is rapidly absorbed following oral administration. It exists in the blood as unbound, protein-bound, and metabolized forms. Ten to twenty percent of trimethoprim is metabolized, primarily in the liver; the remainder is excreted unchanged in the urine. The principal metabolites of trimethoprim are the 1- and 3-oxides and the 3'- and 4'-hydroxy derivatives. The free form is considered to be the therapeutically active form. Approximately 44% of trimethoprim is bound to plasma proteins. Trimethoprim blocks the production of tetrahydrofolic acid from dihydrofolic acid by binding to and reversibly inhibiting the required enzyme, dihydrofolate reductase. This binding is very much stronger for the bacterial enzyme than for the corresponding mammalian enzyme NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abscess (Phase 3)
Acquired Immunodeficiency Syndrome (Phase 4)
Agammaglobulinemia (Phase 2/Phase 3)
Anemia (Phase 4)
Anti-Bacterial Agents (Phase 4)
Ascites (Phase 2)
Aspergillus (Phase 3)
Astrocytoma (Phase 1)
Bacteremia (Phase 3)
Bacterial Infections (Phase 3)
Bacteriuria (Phase 4)
Brain Neoplasms (Phase 1)
Candidemia (Phase 3)
Candidiasis, Invasive (Phase 3)
Child (Phase 3)
Community-Acquired Infections (Phase 2)
Congenital Hyperinsulinism (Phase 2)
Congenital Microtia (Early Phase 1)
Coronavirus Infections (Phase 2)
COVID-19 (Phase 2)
Cystic Fibrosis (Phase 2)
Cystitis (Phase 4)
Deficiency Diseases (Phase 4)
Dentures (Phase 1)
Dermatitis (Phase 2)
Dermatitis, Atopic (Phase 2)
Dermatology (Phase 4)
Diabetes Mellitus, Type 1 (Phase 2)
Diarrhea (Phase 4)
Drug-Related Side Effects and Adverse Reactions (Early Phase 1)
Drug Resistance, Bacterial (Phase 4)
Eczema (Phase 2)
Encephalitis (Phase 4)
Endocarditis (Phase 4)
Enterobacteriaceae Infections (Phase 3)
Epidermolysis Bullosa (Phase 2)
Fungemia (Phase 3)
General Surgery (Phase 4)
Glioblastoma (Phase 1)
Graft Rejection (Phase 4)
Granulomatosis with Polyangiitis (Phase 1/Phase 2)
HIV (Phase 4)
HIV Infections (Phase 4)
Hospitalization (Phase 4)
Idiopathic Pulmonary Fibrosis (Phase 3)
Infant, Newborn (Phase 4)
Infections ()
Kidney Calculi (Phase 4)
Kidney Diseases (Phase 3)
Kidney Failure, Chronic (Phase 2)
Kidney Transplantation (Phase 1/Phase 2)
Leber Congenital Amaurosis (Phase 1/Phase 2)
Leukemia (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1/Phase 2)
Liver Cirrhosis (Phase 2)
Lupus Erythematosus, Systemic (Phase 4)
Lymphoma (Phase 2)
Lymphoproliferative Disorders (Phase 1/Phase 2)
Malaria (Phase 4)
Measles (Phase 3)
Meningitis (Phase 3)
Multiple Myeloma (Phase 3)
Mycoses (Phase 3)
Mycosis Fungoides (Phase 3)
Myelodysplastic Syndromes (Phase 1/Phase 2)
Myeloproliferative Disorders (Phase 1/Phase 2)
Neoplasms (Phase 2/Phase 3)
Neutropenia (Phase 4)
Nutrition Disorders (Phase 3)
Obesity (Phase 4)
Opportunistic Infections (Phase 4)
Osteomyelitis (Phase 2)
Oxidative Stress (Phase 1)
Pancreatic Neoplasms (Phase 1)
Parasitic Diseases (Phase 1/Phase 2)
Pharmacokinetics (Phase 4)
Phencyclidine (Phase 4)
Pituitary Neoplasms (Phase 4)
Pneumocystis (Phase 3)
Pneumocystis Infections (Phase 3)
Pneumonia (Phase 4)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Pregnancy Complications (Phase 3)
Prostatic Hyperplasia (Phase 4)
Prostatic Neoplasms (Phase 4)
Prosthesis-Related Infections (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Pyelonephritis (Phase 4)
Renal Insufficiency, Chronic (Phase 3)
Respiratory Tract Infections (Phase 2)
Sepsis (Phase 3)
Short Bowel Syndrome (Phase 1)
Skin Diseases (Phase 2)
Skin Diseases, Genetic (Phase 2)
Skin Diseases, Infectious (Phase 4)
Staphylococcal Infections (Phase 3)
Staphylococcus aureus (Phase 2)
Thiamine Deficiency (Phase 4)
Toxoplasmosis, Ocular (Phase 3)
Tuberculosis (Phase 4)
Urinary Bladder Neoplasms (Phase 4)
Urinary Bladder, Neurogenic (Phase 4)
Vesico-Ureteral Reflux (Phase 3)
Virus Diseases (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
